[CH3:1][O:2][C:3]1[CH:21]=[CH:20][C:6]([C:7]([C:9]2[C:18](=[O:19])[C:17]3[C:12](=[N:13][CH:14]=[CH:15][CH:16]=3)[NH:11][CH:10]=2)=[O:8])=[CH:5][C:4]=1[CH3:22].C[Si]([N-][Si](C)(C)C)(C)C.[K+].Br[CH2:34][C:35]1[N:40]=[C:39]([C:41]#[N:42])[CH:38]=[CH:37][CH:36]=1>C1COCC1>[CH3:1][O:2][C:3]1[CH:21]=[CH:20][C:6]([C:7]([C:9]2[C:18](=[O:19])[C:17]3[C:12](=[N:13][CH:14]=[CH:15][CH:16]=3)[N:11]([CH2:34][C:35]3[N:40]=[C:39]([C:41]#[N:42])[CH:38]=[CH:37][CH:36]=3)[CH:10]=2)=[O:8])=[CH:5][C:4]=1[CH3:22]Experimental conditions analogous to those described for Step 3 of Example 1, from 50 mg (0.17 mmol) of 3-(4-Methoxy-3-methyl-benzoyl)-1H-[1,8]naphthyridin-4-one in THF 2 ml, was added KHMDS in THF 0.4 ml (0.2 mmol ) slowly. The reaction mixture was stirred at room temperature for 60 min, followed by the addition of 40 mg (0.2 mmol) of 6-Bromomethyl-pyridine-2-carbonitrile. The mixture was heated to 60° C. for 60 min, then quenched with water and purified with HPLC to give the desired product (15 mg). LCMS (M+H)+: 411.1.
Loading…